Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV ketorolac versus rectal indomethacin for prevention of post-ERCP pancreatitis
IRCT20190420043330N1Phase 3Completed
- Sponsor
- Qazvin University of Medical Sciences
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) comparing Indomethacin arm with Ketorolac arm (2 arms). Primary endpoints: Hyperamylasemia, Hyperlipasemia and 11 more. Started May 2019; status: completed.
02
Drugs
ketorolacindomethacin
03
Conditions
post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP)
Beyond the preview
Go deeper on IRCT20190420043330N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190420043330N1.